About Archemix
Archemix is a company based in San Francisco (United States) founded in 2000. It operates as a B2B. Archemix has raised $101.75 million across 2 funding rounds from investors including Atlas Venture, US Trust and Highland Capital Partners. Archemix operates in a competitive market with competitors including Editas Medicine, GBT, LogicBio, Kedrion and Aptamer Group, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Archemix Corp
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$101.75 M (USD)
in 2 rounds
-
Latest Funding Round
$50 M (USD), Series B
Apr 05, 2004
-
Investors
Atlas Venture
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Archemix
Archemix has successfully raised a total of $101.75M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in April 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Archemix
Archemix has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Atlas Venture, US Trust and Highland Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investment and entrepreneur support services.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked | |
|
Investments are made in US life sciences and healthtech firms.
|
Locked | Locked | Locked |
Investor details for Archemix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Archemix
Investment portfolio details for Archemix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Archemix
Detailed financials for Archemix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Archemix Comparisons
Peer comparison for Archemix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Archemix
Archemix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Editas Medicine, GBT, LogicBio, Kedrion and Aptamer Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| Locked | Locked | Locked |
Small molecules are developed for sickle cell disease treatment.
|
|
| Locked | Locked | Locked |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed for hemophilia and immune deficiencies.
|
|
| Locked | Locked | Locked |
Manufacturer of DNA and RNA nucleic acid aptamers for use in research & development
|
|
| Locked | Locked | Locked |
Polysaccharide-based drug for Sickle Cell Disease treatment is developed.
|
Detailed competitors of Archemix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Archemix
Complete news archive for Archemix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Archemix
Archemix was founded in 2000 and raised its 1st funding round 2 years after it was founded.
Archemix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Archemix is a funded company, having raised a total of $101.75M across 2 funding rounds to date.
Archemix, founded in 2000 in San Francisco, United States, focuses on providing healthcare solutions, advancing biotech innovations, therapeutics, and rare diseases. Develops aptamer therapeutics for rare hematological diseases. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Archemix's top competitors include GBT, Editas Medicine and Kedrion.
Archemix has 9 investors. Key investors include Atlas Venture, US Trust, Highland Capital Partners, Prospect Venture Partners, and Rho Capital Partners.